CA3196645A1 - Deuterated aminothiazole compounds as antiviral compounds - Google Patents
Deuterated aminothiazole compounds as antiviral compoundsInfo
- Publication number
- CA3196645A1 CA3196645A1 CA3196645A CA3196645A CA3196645A1 CA 3196645 A1 CA3196645 A1 CA 3196645A1 CA 3196645 A CA3196645 A CA 3196645A CA 3196645 A CA3196645 A CA 3196645A CA 3196645 A1 CA3196645 A1 CA 3196645A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- deuterium
- herpes
- compounds
- ore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20204545.6 | 2020-10-29 | ||
| EP20204545 | 2020-10-29 | ||
| PCT/EP2021/080023 WO2022090409A1 (en) | 2020-10-29 | 2021-10-28 | Deuterated aminothiazole compounds as antiviral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3196645A1 true CA3196645A1 (en) | 2022-05-05 |
Family
ID=73037895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3196645A Pending CA3196645A1 (en) | 2020-10-29 | 2021-10-28 | Deuterated aminothiazole compounds as antiviral compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12552756B2 (enExample) |
| EP (1) | EP4237414A1 (enExample) |
| JP (1) | JP2023552274A (enExample) |
| KR (1) | KR20230131177A (enExample) |
| CN (1) | CN116783171A (enExample) |
| AU (1) | AU2021367976A1 (enExample) |
| CA (1) | CA3196645A1 (enExample) |
| MX (1) | MX2023004955A (enExample) |
| WO (1) | WO2022090409A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4466255A1 (en) | 2022-01-17 | 2024-11-27 | Innovative Molecules GmbH | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
| IL325911A (en) | 2023-07-17 | 2026-03-01 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| GEP20207128B (en) * | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| MX2020003369A (es) * | 2017-10-05 | 2020-07-29 | Innovative Molecules Gmbh | Enantiomeros de tiazoles sustituidos como compuestos antivirales. |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
-
2021
- 2021-10-28 KR KR1020237017885A patent/KR20230131177A/ko active Pending
- 2021-10-28 US US18/034,099 patent/US12552756B2/en active Active
- 2021-10-28 CA CA3196645A patent/CA3196645A1/en active Pending
- 2021-10-28 AU AU2021367976A patent/AU2021367976A1/en active Pending
- 2021-10-28 WO PCT/EP2021/080023 patent/WO2022090409A1/en not_active Ceased
- 2021-10-28 JP JP2023526237A patent/JP2023552274A/ja active Pending
- 2021-10-28 EP EP21802293.7A patent/EP4237414A1/en active Pending
- 2021-10-28 CN CN202180088642.XA patent/CN116783171A/zh active Pending
- 2021-10-28 MX MX2023004955A patent/MX2023004955A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116783171A (zh) | 2023-09-19 |
| AU2021367976A9 (en) | 2025-03-13 |
| EP4237414A1 (en) | 2023-09-06 |
| KR20230131177A (ko) | 2023-09-12 |
| US20230391738A1 (en) | 2023-12-07 |
| MX2023004955A (es) | 2023-05-17 |
| WO2022090409A1 (en) | 2022-05-05 |
| US12552756B2 (en) | 2026-02-17 |
| AU2021367976A1 (en) | 2023-06-08 |
| JP2023552274A (ja) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12295945B2 (en) | Enantiomers of substituted thiazoles as antiviral compounds | |
| EP3565815B1 (en) | Compounds as bcl-2-selective apoptosis-inducing agents | |
| EP3209656B1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| US12552756B2 (en) | Deuterated aminothiazole compounds as antiviral compounds | |
| SG11202108519TA (en) | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | |
| KR20240134979A (ko) | 헬리카제-프라이마제 억제제의 고체 결정형 및 이의 제조 방법 | |
| US20160368944A1 (en) | Linked purine pterin hppk inhibitors useful as antibacterial agents | |
| KR101730790B1 (ko) | 세로토닌 5-ｈｔ6 저해 활성을 갖는 5,6,7,8-테트라하이드로퀴나졸린-2-아민 화합물 | |
| EP4247778A1 (en) | Agents for treating disorders involving ryanodine receptors | |
| EP4422747A1 (en) | Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 | |
| WO2026035901A1 (en) | Tricyclic compounds for treatment of hsv | |
| EP4422748A1 (en) | Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 | |
| WO2026035900A1 (en) | Tricyclic compounds for treatment of hsv | |
| EP4422753A1 (en) | Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 | |
| WO2025067411A1 (zh) | 一种nek7抑制剂、药物组合物及其用途 | |
| HK1235064A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| KR20000051515A (ko) | 항바이러스 활성을 가지는 2-아미노퓨린 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241014 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241014 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241014 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250625 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250625 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250821 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250829 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250829 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250829 |